Related references
Note: Only part of the references are listed.A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients
Thomas Yau et al.
INVESTIGATIONAL NEW DRUGS (2022)
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Christian Recher et al.
LEUKEMIA (2022)
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial
Mike Dennis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Stephen L. Chan et al.
INVESTIGATIONAL NEW DRUGS (2021)
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors
Paul N. M. Cheng et al.
INVESTIGATIONAL NEW DRUGS (2021)
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer
Peter W. Szlosarek et al.
CANCER MEDICINE (2021)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chong Chyn Chua et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia
Francis Mussai et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
Carmela De Santo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Molecular basis and current strategies of therapeutic arginine depletion for cancer
Livingstone Fultang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target
Francis Mussai et al.
BLOOD (2015)
Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma
Thomas Yau et al.
INVESTIGATIONAL NEW DRUGS (2015)
Applicability of a Pick a Winner trial design to acute myeloid leukemia
Robert K. Hills et al.
BLOOD (2011)